Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) Net income
Merck & Co., Inc.'s net income for fiscal 2025 was $18.3B, up 6.60% from $17.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.2B. Over the past ten years it has ranged from $377.0M (fiscal 2023) to $18.3B (fiscal 2025) — the current reading is the highest in ten years. Merck & Co., Inc. ranks 12th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $18.3B | 6.60% |
| FY2024 | $17.1B | 4,444.56% |
| FY2023 | $377.0M | (97.40%) |
| FY2022 | $14.5B | 17.54% |
| FY2021 | $12.4B | 173.23% |
| FY2020 | $4.5B | (19.32%) |
| FY2019 | $5.6B | (9.48%) |
| FY2018 | $6.2B | 156.12% |
| FY2017 | $2.4B | (38.65%) |
| FY2016 | $3.9B | (11.62%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$1.3B | — |
| Mar 2026 | −$4.2B | — |
| Dec 2025 | $3.0B | (48.82%) |
| Sep 2025 | $5.8B | 30.66% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| JNJ Johnson & Johnson compare | $21.0B |
| NVO Novo Nordisk A/S compare | $17.9B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| AMGN Amgen Inc. compare | $8.7B |
| ABBV AbbVie Inc. compare | $6.3B |
| PFE Pfizer Inc. compare | $4.4B |
| MRK Merck & Co., Inc. | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on MRK
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement